Pfizer abandons Alzheimer’s and Parkinson’s research

The company doesn't see a future in it

Pfizer has announced that it is pulling out of early-stage research into Alzheimer’s and Parkinson’s disease after investing heavily in the area in recent years.


The pharmaceutical giant has said in a statement that its money can be spent more productively elsewhere.

“This was an exercise to reallocate spend across our portfolio — to focus on those areas where our pipeline,